key: cord-1029845-ehht4q8j authors: Ng, Alexander title: Graft Injury and Re-transplantation in Liver Transplant patients with COVID-19 date: 2021-04-23 journal: nan DOI: 10.1016/j.liver.2021.100008 sha: e850b70bd153663cb98336a01ed342c82d832279 doc_id: 1029845 cord_uid: ehht4q8j This article discusses the current scene of liver transplantation (LT) in light of the impact of COVID-19, with particular emphasis on the possibility of graft injury and re-transplantation in LT patients infected with SARS-CoV-2. A major concern is whether such patients experience more severe form of disease thus higher risk of acute, irreversible liver injury. If serious, this may necessitate re-transplantation. It aims to raise awareness in this relatively under-researched domain. More studies are required to evaluate the issue since it has strong implications in healthcare resource allocation and clinical decision-making. Several potential research directions are proposed, including the possibility of prolonging bridging therapy for non-urgent LT cases in patients with hepatocellular carcinoma and whether hepatoprotective agents play a role in liver-sparing during SARS-CoV-2 infection. There is also discussion of the relevance of lung injury in LT patients with COVID-19 since it is not uncommon regarding the high expression of ACE2 receptors in the lungs, and that lung injury remains the major cause of death in patients with chronic liver disease. The sole author is responsible for all aspects of the production of the manuscript. There are no acknowledgements. No ethics approval is required. This article discusses the current scene of liver transplantation (LT) in light of the impact of COVID-19, with particular emphasis on the possibility of graft injury and re-transplantation in LT patients infected with SARS-CoV-2. A major concern is whether such patients experience more severe form of disease thus higher risk of acute, irreversible liver injury. If serious, this may necessitate retransplantation. It aims to raise awareness in this relatively under-researched domain. More studies are required to evaluate the issue since it has strong implications in healthcare resource allocation and clinical decision-making. Several potential research directions are proposed, including the possibility of prolonging bridging therapy for non-urgent LT cases in patients with hepatocellular carcinoma and whether hepatoprotective agents play a role in liver-sparing during SARS-CoV-2 infection. There is also discussion of the relevance of lung injury in LT patients with COVID-19 since it is not uncommon regarding the high expression of ACE2 receptors in the lungs, and that lung injury remains the major cause of death in patients with chronic liver disease. Liver transplantation has faced unprecedented challenges since the emergence of SARS-CoV-2 in Wuhan (China). In the US, numbers of living and deceased donor liver transplants (LTs) performed weekly decreased significantly from January to March 2020. 1 One should also not forget the importance of lung injury in LT patients with COVID-19. Efforts to treat liver injury should complement existing treatment paradigms to cope with lung injury, since COVID-19-related lung injury is the most common cause of mortality in COVID-19 patients with chronic liver disease. This is evidenced by Marjot, Moon and colleagues, where only 19% of all deceased patients died of liver-related complications. 16 Moreover, concomitant lung and liver injury amidst COVID-19 is not uncommon. According to Li and colleagues, the levels of expression of ACE2 receptors in the lungs and the liver are similar. 17 Fortunately, trials are underway to explore the efficacy of immunosuppressants in mitigating the harms resultant from lung injury. It is also interesting to see whether The TACROVID trial investigated the clinical utility of methylprednisolone pulses and tacrolimus in treating patients with severe COVID-19 pneumonia. 18 Of interest, the combination is found to be beneficial. Where tacrolimus-based immunosuppression does exhibit an advantage in mitigating lung injury, clinicians may be more inclined to continue immunosuppression by switching to, or maintaining the use of, tacrolimus. Moreover, the RuXoCoil trial aims to investigate the efficacy of ruxolitinib, a JAK1/2 inhibitor, in reducing the extent of lung injury experienced by patients with COVID-19. 19 Trial results are pending, but the efforts of the trial investigators should be commended. Adding ruxolitinib, or other JAK inhibitors to the immunosuppression regimen in LT patients with COVID-19 is potentially beneficial due to further amelioration of pulmonary health during the disease course. Although JAK inhibitor-induced hyperlipidaemia may raise a concern in patients whose indication for LT is metabolic-associated fatty liver disease (with many having metabolic syndrome), 20 this can be monitored regularly and controlled by polypharmacy such as statins, if necessary. More studies are also required to elucidate on the interactions between JAK inhibitors and existing immunosuppressants for LT patients safe for use in COVID-19. LT in the era of COVID-19 is challenging. Nevertheless, obstacles are not insurmountable. The Impact of COVID-19 on Organ Donation, Procurement, and Liver Transplantation in the United States Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases A systematic review and meta-analysis of the COVID-19 associated liver injury Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID-19): U.S. Multicenter Experience COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature COVID-19 and the liver: little cause for concern Liver injury in liver transplant patients with COVID-19: a histopathological confirmation Liver Transplantation in the Time of COVID19: Barriers and Ethical Considerations for Management and Next Steps Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol National Library of Medicine (US) Clinical efficacy of tofacitinib in moderate to severe ulcerative colitis Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study Covid-19 in liver transplant recipients: the French SOT COVID registry COVID-19 in an international European liver transplant recipient cohort